Aytu Biopharma Inc (AYTU)
1.1800 x 2 1.3800 x 10
Post-market by (Cboe BZX)
1.2400 -0.0100 (-0.80%) 03/21/25 [NASDAQ]
1.1800 x 2 1.3800 x 10
Post-market 1.2400 unch (unch) 16:00 ET
for Fri, Mar 21st, 2025
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
06-2024 | 06-2023 | 06-2022 | 06-2021 | 06-2020 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 20,006 | 22,985 | 19,360 | 49,901 | 48,333 |
Receivables | 23,617 | 28,937 | 21,712 | 28,176 | 5,633 |
Inventories | 12,633 | 11,995 | 10,849 | 16,339 | 9,999 |
Other current assets | 0 | 0 | 633 | 1,038 | 5,742 |
TOTAL | $61,891 | $71,079 | $59,929 | $105,234 | $75,422 |
Non-Current Assets | |||||
PPE Net | 693 | 1,815 | 3,025 | 5,140 | 259 |
Intangibles | 52,453 | 58,970 | 70,632 | 151,266 | 76,945 |
Other Non-Current Assets | 3,058 | 4,599 | 4,037 | 4,028 | 667 |
TOTAL | $56,204 | $65,384 | $77,694 | $160,434 | $77,871 |
Total Assets | $118,095 | $136,463 | $137,623 | $265,668 | $153,293 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | 4,252 | 1,648 | 3,909 | 24,602 | 3,322 |
Accounts payable and accrued liabilities | 10,440 | 13,478 | 10,987 | 19,255 | 11,640 |
Accrued Expenses | 38,574 | 46,799 | 44,187 | 57,234 | 11,948 |
Other current liabilities | 8,962 | 7,090 | 5,359 | 8,347 | 1,553 |
TOTAL | $62,228 | $69,015 | $64,442 | $109,438 | $28,763 |
Non-Current Liabilities | |||||
Long Term Debt | 10,877 | 14,713 | 14,279 | 180 | 11,172 |
aiOther Non-Current Liabilities | 17,274 | 13,378 | 14,594 | 18,482 | 18,343 |
TOTAL | $28,151 | $28,091 | $28,873 | $18,662 | $29,515 |
Total Liabilities | $90,379 | $97,106 | $93,315 | $128,100 | $58,278 |
Shareholders' Equity | |||||
Shares Outstanding, K | 6,149 | 5,530 | 3,122 | 1,378 | 629 |
Common Shares | 1 | 1 | 0 | 3 | 1 |
Retained earnings | -319,973 | -304,129 | -287,078 | -178,299 | -120,010 |
TOTAL | $27,716 | $39,357 | $44,308 | $137,568 | $95,015 |
Total Liabilities And Equity | $118,095 | $136,463 | $137,623 | $265,668 | $153,293 |